©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Apr 16, 2022; 10(11): 3414-3425
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3414
Published online Apr 16, 2022. doi: 10.12998/wjcc.v10.i11.3414
Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma
Rui-Xue Huo, Yu Cui, Long Zhang, Wen-Hua Zhang, Yu-Mei Cai, Cheng-Cheng Zheng, Rui-Xue Cui, Qian-Ye Wang, Zhen Sun, Feng-Wei Wang, Department of Oncology, Tianjin Union Medical Center, Tianjin 300000, China
Ying-Ying Jin, Yong-Xue Zhuo, Xiao-Tong Ji, School of Medicine, Nankai University, Tianjin 300000, China
Xiao-Jing Wu, Yi-Jia Wang, Laboratory of Oncologic Molecular Medicine, Tianjin Union Medical Center, Tianjin 300000, China
Author contributions: Wang FW contributed to the conception of the study; Huo RX performed the Clinical trial; Jin JY, Zhuo YX, and Ji XT contributed significantly to follow-up, analysis and manuscript preparation; Cui Y, Wu XJ, Wang YJ, Zhang L, Zhang WH, and Cai YM performed the data analyses and wrote the manuscript; Zheng CC, Cui RX, Wang QY, and Sun Z helped perform the analysis with constructive discussions.
Supported by Tianjin Science and Technology Plan Project , No. 19YFZCSY00170 ; Tianjin Union Medical center , No. 2019YJ007 ; and Beijing medical and health foundation , No. F1814B .
Institutional review board statement: The study was reviewed and approved by the China Ethics Committee of Registering Clinical Trials (No. ChiECRCT20170178).
Conflict-of-interest statement: The authors have no conflict of interests to disclose.
Data sharing statement: Technical appendix, statistical code, and dataset are available from the corresponding author at wfengwei2004@163.com. Participants gave informed consent for data sharing.
Corresponding author: Feng-Wei Wang, MD, PhD, Chief Doctor, Department of Oncology, Tianjin Union Medical Center, No. 190 jieyuan Road, Hongqiao District, Tianjin 300000, China. wfengwei2004@163.com
Received: September 20, 2021
Peer-review started: September 20, 2021
First decision: January 10, 2022
Revised: January 14, 2022
Accepted: March 6, 2022
Article in press: March 6, 2022
Published online: April 16, 2022
Processing time: 199 Days and 22.9 Hours
Peer-review started: September 20, 2021
First decision: January 10, 2022
Revised: January 14, 2022
Accepted: March 6, 2022
Article in press: March 6, 2022
Published online: April 16, 2022
Processing time: 199 Days and 22.9 Hours
Core Tip
Core Tip: Our article focuses on the comprehensive treatments of head and neck squamous cell carcinoma, especially for recurred tumors after surgery or tumor lesions that could not be surgically removed.